Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Angelini

Showing results (81-90 of 531) with videos related to

Pageof 54
Sort By:
Neuromuscular Disorders : NMD|July 19, 2003
LGMD2E patients risk developing dilated cardiomyopathyM Fanin, P Melacini, C Boito, et al.
Neuromuscular Disorders : NMD|March 1, 1995
Discordant clinical outcome in myotonic dystrophy relatives showing (CTG)n > 700 repeatsG Novelli, M Gennarelli, E Menegazzo, et al.
Acta Neuropathologica. Supplementum|January 1, 1981
Myopathological findings in progressive myoclonus epilepsyS Pierobon-Bormioli, C Angelini, M Armani, et al.
Transactions of the American Neurological Association|January 1, 1973
Mitochondria-lipid-glycogen (MLG) disease of muscle: a morphologically regressive congenital myopathyF Jerusalem, C Angelini, A G Engel, et al.
Zygote (Cambridge, England)|July 28, 2021
Time-dependent expression of ryanodine receptors in sea urchin eggs, zygotes and early embryosG Percivale, C Angelini, C Falugi, et al.
Wilderness & Environmental Medicine|May 7, 2002
Increased aldosterone levels in acute mountain sickness at Capanna Regina MargheritaC Angelini, A Cogo, G Madrigale, et al.
Clinical Biochemistry|February 1, 1987
Clinical varieties of carnitine and carnitine palmitoyltransferase deficiencyC Angelini, C Trevisan, G Isaya, et al.
Cell Calcium|July 6, 2002
Muscarinic signalling affects intracellular calcium concentration during the first cell cycle of sea urchin embryosP K Harrison, C Falugi, C Angelini, et al.
Neuropathology and Applied Neurobiology|February 4, 2009
Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChRS Martignago, M Fanin, E Albertini, et al.
Child and Adolescent Psychiatric Clinics of North America|June 13, 2022
Cardiovascular Considerations for Stimulant Class MedicationsPaul Hammerness, Amy Berger, Michael C Angelini, et al.
Pageof 54

Showing results (81-90 of 531) with videos related to

Sort By:
Pageof 54
Neuromuscular Disorders : NMD|July 19, 2003
LGMD2E patients risk developing dilated cardiomyopathyM Fanin, P Melacini, C Boito, et al.
Neuromuscular Disorders : NMD|March 1, 1995
Discordant clinical outcome in myotonic dystrophy relatives showing (CTG)n > 700 repeatsG Novelli, M Gennarelli, E Menegazzo, et al.
Acta Neuropathologica. Supplementum|January 1, 1981
Myopathological findings in progressive myoclonus epilepsyS Pierobon-Bormioli, C Angelini, M Armani, et al.
Transactions of the American Neurological Association|January 1, 1973
Mitochondria-lipid-glycogen (MLG) disease of muscle: a morphologically regressive congenital myopathyF Jerusalem, C Angelini, A G Engel, et al.
Zygote (Cambridge, England)|July 28, 2021
Time-dependent expression of ryanodine receptors in sea urchin eggs, zygotes and early embryosG Percivale, C Angelini, C Falugi, et al.
Wilderness & Environmental Medicine|May 7, 2002
Increased aldosterone levels in acute mountain sickness at Capanna Regina MargheritaC Angelini, A Cogo, G Madrigale, et al.
Clinical Biochemistry|February 1, 1987
Clinical varieties of carnitine and carnitine palmitoyltransferase deficiencyC Angelini, C Trevisan, G Isaya, et al.
Cell Calcium|July 6, 2002
Muscarinic signalling affects intracellular calcium concentration during the first cell cycle of sea urchin embryosP K Harrison, C Falugi, C Angelini, et al.
Neuropathology and Applied Neurobiology|February 4, 2009
Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChRS Martignago, M Fanin, E Albertini, et al.
Child and Adolescent Psychiatric Clinics of North America|June 13, 2022
Cardiovascular Considerations for Stimulant Class MedicationsPaul Hammerness, Amy Berger, Michael C Angelini, et al.
Pageof 54